Effectiveness and durability of benefit of mTOR inhibitors (mTORi) in a real-world cohort of metastatic prostate cancer (mPCA) patients with PI3K pathway alterations. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback